Former GSK cancer R&D chief Paoletti takes the reins at GammaDelta; Blueprint inks big Cambridge lease

Paolo Paoletti, the former president of GSK’s oncology R&D group, has taken the helm at Abingworth-backed GammaDelta Therapeutics. “I’m extremely excited to take on this role to further advance the pioneering research on gamma delta (γδ) T cells of the company’s founders, Professor Adrian Hayday and Dr Oliver Nussbaumer at King’s College London and the Francis Crick Institute,” Paoletti said in a statement. “The unique properties of γδ T cells, coupled with the proprietary knowledge of the company offer great prospects for the development of innovative immunotherapies for many forms of cancers, including solid tumours, and potentially auto-inflammatory diseases.” Pfizer vet Natalie Mount joined the biotech as CSO.

Blueprint CEO Jeff Albers has inked a new lease for 100,000 square feet in Cambridge, MA, according to the Boston Business Journal.

NewLink $NLNK says that it has “a next-generation compound, a novel prodrug of indoximod, NLG802, which we expect to enter the clinic by the end of Q3 this year.”

The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

PODD 2017

BioNJ CEO Summit 2017